The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...
AL-S Pharma is planning a registrational study for its amyotrophic lateral sclerosis (ALS) monoclonal antibody (mAb), AP-101, after the drug met its efficacy and safety endpoints in a mid-stage trial.
A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...
ZURICH, Switzerland, Dec. 5, 2025 /PRNewswire/ -- AL-S Pharma, a clinical-stage biotech company dedicated to the development of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS) today ...
The MarketWatch News Department was not involved in the creation of this content. -- CDA issues positive reimbursement recommendation for QALSODY -- INESSS recognizes QALSODY's promising clinical ...
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS ...
(RTTNews) - Biogen Inc. (BIIB) said The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results